Trans-Pacific Partnership Trade Agreement Could Restrict Access To Affordable, Life-Saving Drugs
In this post in the PLoS “Speaking of Medicine” blog, Judit Rius Sanjuan, a lawyer from Barcelona, Spain, and the U.S. manager of the Access Campaign at Medecins Sans Frontieres (MSF), says the Trans-Pacific Partnership (TPP), a regional trade agreement that currently involves 11 countries but could expand to include other countries in the Asia-Pacific region, “threatens to set a dangerous precedent with damaging implications for developing countries where MSF works, and beyond.” “Negotiations are being conducted in secret, but leaked drafts of the agreement outline U.S. aggressive intellectual property (IP) demands that that could severely restrict access to affordable, life-saving medicines for millions of people,” she writes, concluding, “At this pivotal moment in the fight against AIDS, when the scientific, medical and policy tools needed to reverse the epidemic are finally at hand, … the U.S. government’s demands in the TPP will threaten so much of what has been achieved so far, and will make the vision of an AIDS-free generation impossible, or at least much more expensive” (8/7).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.